Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance

Ashwani Sharma,1 Tarun Virmani,1 Anjali Sharma,2 Vaishnavi Chhabra,1 Girish Kumar,1 Kamla Pathak,3 Abdulsalam Alhalmi4 1School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, 121105, India; 2Freelancer, Pharmacovigilance Expert, Uttar Pradesh, India; 3Faculty of Pharmacy, Uttar Pradesh...

Full description

Bibliographic Details
Main Authors:	Sharma A, Virmani T, Chhabra V, Kumar G, Pathak K, Alhalmi A
Format:	Article
Language:	English
Published:	Dove Medical Press 2022-06-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	dpp-4 insulin incretins glucose intolerance liver diseases sitagliptin dpp-4 inhibitors.
Online Access:	https://www.dovepress.com/potential-effect-of-dpp-4-inhibitors-towards-hepatic-diseases-and-asso-peer-reviewed-fulltext-article-DMSO

Similar Items

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
by: Kunika Saini, et al.
Published: (2023-05-01)

Assessment of Factors Affecting Therapeutic Response of the DPP-4 Inhibitor Sitagliptin in A Sample of Iraqi Type 2 Diabetic Patients
by: Ahmad Nazar Jawad, et al.
Published: (2024-07-01)

DPP4 in Diabetes
by: Diana eRöhrborn, et al.
Published: (2015-07-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01)

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer
by: Chintan Shah, et al.
Published: (2020-03-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
by: Hugo Ramos, et al.
Published: (2022-07-01)

DPP‐4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia
by: Dwight D. Harris, et al.
Published: (2024-03-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Clinical Use of DPP-4 Inhibitors
by: Baptist Gallwitz
Published: (2019-06-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
by: Jonathan V. Mui, et al.
Published: (2021-10-01)

Oat globulin peptides regulate antidiabetic drug targets and glucose transporters in Caco-2 cells
by: Feng Wang, et al.
Published: (2018-03-01)

DPP4 Regulates the Th17/IL-17 Axis and Accelerates Epithelial Mesenchymal Transition to Promote Ovalbumin-Induced Asthma in Female C57BL/6J Mice
by: Linqiao Li, et al.
Published: (2023-12-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

HYPOGLYCEMIC EFFECT OF SITAGLIPTIN AND AMINOGUANIDINE COMBINATION IN EXPERIMENTAL DIABETES MELLITUS
by: D. V. Kurkin, et al.
Published: (2023-02-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

Sitagliptin eye drops prevent the impairment of retinal neurovascular unit in the new Trpv2 +/− rat model
by: Hugo Ramos, et al.
Published: (2024-11-01)

Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021-12-01)

Gut microbiota DPP4-like enzymes are increased in type-2 diabetes and contribute to incretin inactivation
by: Marta Olivares, et al.
Published: (2024-07-01)

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
by: Vishal Mathur, et al.
Published: (2023-08-01)

Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay
by: Pallavi Kishor Vawhal, et al.
Published: (2023-01-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

Synthesis of Rottlerone Analogues and Evaluation of Their α-Glucosidase and DPP-4 Dual Inhibitory and Glucose Consumption-Promoting Activity
by: Yinan Zhang, et al.
Published: (2021-02-01)

DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
by: Jianqiang Zhang, et al.
Published: (2019-05-01)

Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
by: Naoko Tajima, et al.
Published: (2020-05-01)

New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-12-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study
by: Hiroshi Sakura, et al.
Published: (2016-12-01)

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
by: Mei-Tzu Wang, et al.
Published: (2017-07-01)

Alogliptin – the new member of DPP-4 inhibitors class
by: Nina Aleksandrovna Petunina, et al.
Published: (2014-12-01)

Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis
by: Shuyang Traub, et al.
Published: (2017-03-01)

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
by: Derek Ge, et al.
Published: (2022-12-01)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
by: Alina Babenko, et al.
Published: (2014-12-01)

Novel Potent and Selective DPP-4 Inhibitors: Design, Synthesis and Molecular Docking Study of Dihydropyrimidine Phthalimide Hybrids
by: Ahmed A. E. Mourad, et al.
Published: (2021-02-01)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
by: Seon-Ah Cha, et al.
Published: (2017-04-01)